- Home
- Equipment
- usa massachusetts
- intravenous infusion
Show results for
Refine by
Intravenous Infusion Equipment Supplied In Usa Massachusetts
6 equipment items found
Manufactured by:Sage Therapeutics based inCambridge, MASSACHUSETTS (USA)
ZULRESSO™ is a prescription medicine used to treat Postpartum Depression in ...
Manufactured by:Alnylam Pharmaceuticals, Inc. based inCambridge, MASSACHUSETTS (USA)
ONPATTRO is a prescription medicine for adults that treats the polyneuropathy caused by an illness called hereditary ATTR (hATTR) ...
Manufactured by:SQ Innovation, Inc. based inBurlington, MASSACHUSETTS (USA)
Lasix ONYU is an advanced prescription drug-device combination designed specifically for the treatment of edema in adults suffering from chronic heart failure. This innovative product represents a shift from traditional oral and intravenous methods by introducing a high-concentration formulation of furosemide for subcutaneous infusion. Each prefilled cartridge ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indications: Barhemsys is a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indications: BELRAPZO® (bendamustine hydrochloride injection) is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. BELRAPZO® (bendamustine hydrochloride injection) is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indications: BENDEKA® is indicated for the treatment of patients with Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established. Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing ...